Protection against Reinfection with the Omicron BA.2.75 Subvariant
Date
2023-01-01Author
Chemaitelly, HiamTang, Patrick
Coyle, Peter
Yassine, Hadi M.
Al-Khatib, Hebah A.
Smatti, Maria K.
Hasan, Mohammad R.
Ayoub, Houssein H.
Altarawneh, Heba N.
Al-Kanaani, Zaina
Al-Kuwari, Einas
Jeremijenko, Andrew
Kaleeckal, Anvar H.
Latif, Ali N.
Shaik, Riyazuddin M.
Abdul-Rahim, Hanan F.
Nasrallah, Gheyath K.
Al-Kuwari, Mohamed G.
Butt, Adeel A.
Al-Romaihi, Hamad E.
Al-Thani, Mohamed H.
Al-Khal, Abdullatif
Bertollini, Roberto
Abu-Raddad, Laith J.
...show more authors ...show less authors
Metadata
Show full item recordAbstract
The BA.2.75 sublineage of the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may escape neutralizing antibodies. The BA.2.75 sublineage (primarily the BA.2.75.2 subvariant) became the predominant sublineage in Qatar by September 10, 2022 (Section S1 and Fig. S1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). We estimated the effectiveness of previous infection with SARS-CoV-2 in preventing reinfection with BA.2.75 using a test-negative, case–control study design (Section S2).1
Collections
- Biomedical Research Center Research [738 items ]